CML
News
AMP publishes report on DNA variants in CMNs
A new report addresses the clinical relevance of DNA variants in chronic myeloid neoplasms (CMNs). The report is intended to aid clinical...
News
Familial risk of myeloid malignancies
A large study has revealed “the strongest evidence yet” supporting genetic susceptibility to myeloid malignancies, according to a researcher. The...
News
Global burden of hematologic malignancies
Research has shown an increase in the global incidence of leukemia and non-Hodgkin lymphoma (NHL) in recent years. The Global Burden of Disease (...
News
Diabetics have higher risk of hematologic, other cancers
A review of data from more than 19 million people indicates that diabetes significantly raises a person’s risk of developing cancer. When...
News
EC approves new use, formulation of dasatinib
The European Commission (EC) has expanded the marketing authorization for dasatinib (Sprycel). The drug is now approved to treat patients ages 1...
Conference Coverage
Novel targeted cancer drugs cause fewer arrhythmias
Tyrosine kinase inhibitors and other targeted agents have 40% lower cardiac arrhythmia risk than anthracycline-based regimens.
News
Cost of imatinib still high despite generic options, team says
The availability of generic imatinib has had limited effects on costs of the drug, according to research published in Health Affairs. Data...
News
CHMP backs approval of dasatinib for kids
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended changes to the marketing authorization for...
From the Journals
Do industry payments increase prescribing for some targeted therapies?
Some oncologists prescribing treatments for CML and RCC were more likely to prescribe a drug when they had received general payments from the drug...
News
Agent exhibits activity in leukemias, MDS
The experimental agent prexigebersen (formerly BP1001) was considered well-tolerated and demonstrated early evidence of activity against relapsed/...
News
FDA approves nilotinib for children with CML
The decision expands the drug’s indication to include first- and second-line use in children.